Blume Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Blume Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2	Closed	-$142	–	452
2025 Q1	$142	Buy	+2	New	+$135	﹤0.01%	444
2019 Q1	–	Sell	-270	Closed	-$23K	–	226
2018 Q4	$23K	Buy	+270	New	+$25.7K	0.01%	160
2015 Q2	–	Sell	-80	Closed	-$10K	–	247
2015 Q1	$10K	Hold	80	–	–	0.01%	225
2014 Q4	$7K	Buy	+80	New	+$6.65K	﹤0.01%	254
2014 Q1	–	Sell	-16	Closed	-$1K	–	236
2013 Q4	$1K	Buy	+16	New	+$1.09K	﹤0.01%	256

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Blume Capital Management's BMRN Position: Q2 2025 in Review

Blume Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2025, closing a stake of 2 shares — an estimated $142 sold.

Blume Capital Management first reported a position in BMRN in Q4 2013 and held it in 5 quarters. The position peaked at $23K in Q4 2018. 582 funds tracked by Wall St. Rank hold BMRN as of Q2 2025.

Blume Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Blume Capital Management sold 2 BioMarin Pharmaceuticals shares in Q2 2025, an estimated $142.
Blume Capital Management first reported a position in BioMarin Pharmaceuticals in Q4 2013 and held it in 5 quarters.
Blume Capital Management's BioMarin Pharmaceuticals position peaked at $23K in Q4 2018.
582 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2025.

Based on Blume Capital Management's 13F filing for Q2 2025, filed 30 Jul 2025.